Physician profile
Ebrahim Hazany
NPI 1346359304
$12,659.83
in general payments reported to CMS, 2019-2025
30 companies · $2,122 in 2025
The $2,122 reported for 2025 was more than what 90% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,893 · 2020: $534 · 2021: $1,726 · 2022: $2,100 · 2023: $2,466 · 2024: $1,819 · 2025: $2,122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,395 · Travel and Lodging: $9.00 · Education: $3.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,395.23 |
| Travel and Lodging | $9.00 |
| Education | $3.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,521.13 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $1,369.95 | 2021-2025 | Ingrezza |
| Bausch Health US, LLC | $1,190.63 | 2019-2025 | Aplenzin, Wellbutrin |
| Otsuka America Pharmaceutical, INC. | $1,093.50 | 2019-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,056.43 | 2022-2025 | Caplyta |
| Lundbeck LLC | $1,013.30 | 2019-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $738.66 | 2019-2023 | Hetlioz, Fanapt |
| Janssen Pharmaceuticals, INC | $680.66 | 2019-2025 | Spravato |
| Allergan, INC. | $643.31 | 2019-2020 | |
| Corium, LLC | $619.66 | 2022-2025 | Azstarys |
| Almatica Pharma LLC | $399.34 | 2021-2025 | Loreev Xr, Gralise |
| Axsome Therapeutics, INC. | $362.19 | 2023-2025 | Auvelity |
| Alkermes, INC. | $323.11 | 2020-2025 | Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $264.67 | 2019-2025 | Trintellix |
| Neos Therapeutics, LP | $243.97 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $236.04 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $198.79 | 2019-2024 | Ajovy |
| Idorsia Pharmaceuticals US INC | $156.01 | 2022-2024 | Quviviq |
| Arbor Pharmaceuticals, INC. | $150.37 | 2019-2021 | |
| Eisai INC. | $86.35 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $78.37 | 2021-2022 | |
| Biogen, INC. | $59.07 | 2023 | |
| Tris Pharma INC | $38.51 | 2025 | Quillivant, Dyanavel Xr |
| Merck Sharp & Dohme LLC | $23.16 | 2021 | |
| Ironshore Pharmaceuticals INC. | $22.49 | 2019 | |
| Owp Pharmaceuticals, INC. | $20.35 | 2023 | Subvenite, Lamotrigine |
| Noven Therapeutics, LLC | $20.21 | 2023 | Xelstrym |
| Orexo US, INC. | $19.44 | 2019 | |
| Adlon Therapeutics L.P. | $16.16 | 2021 | |
| Shire North American Group INC | $14.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ebrahim Hazany listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.